New study identifies biological mechanism driving therapy resistance in advanced prostate cancer

Researchers have discovered that the depletion of a specific tRNA molecule drives therapy resistance in advanced prostate cancer by allowing cells to change their identity. This biological mechanism could lead to new treatments that resensitize aggressive tumors to existing therapies.
Why it matters
Understanding this mechanism offers a potential breakthrough in treating therapy-resistant prostate cancer, a leading cause of cancer death in men.
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Anna Tarazevich from Pexels A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
Published in Nature , the study reveals that a specific transfer RNA (tRNA) named tRNAArg (UCU)-1 plays a central role in allowing prostate cancer cells to escape targeted therapies and transition into more aggressive and treatment-resistant forms of the disease. This finding could help researchers develop a way to resensitize resistant tumors to existing therapies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in